Stevanato Group S.p.A. (STVN)
USD 21.38
(3.09%)
USD 21.38
(3.09%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 272.34 Million EUR | 21.1% |
| 2022 | 256.4 Million EUR | 17.83% |
| 2021 | 226.92 Million EUR | 16.87% |
| 2020 | 156.37 Million EUR | 45.58% |
| 2019 | 106.53 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 45.87 Million EUR | -42.93% |
| 2024 Q2 | 45.49 Million EUR | 10.84% |
| 2023 Q1 | 59.2 Million EUR | -16.49% |
| 2023 FY | - EUR | 21.1% |
| 2023 Q4 | 79.03 Million EUR | 41.13% |
| 2023 Q3 | 56 Million EUR | 8.53% |
| 2023 Q2 | 51.6 Million EUR | -12.85% |
| 2022 Q2 | 59.88 Million EUR | 12.32% |
| 2022 Q1 | 53.31 Million EUR | -9.33% |
| 2022 FY | - EUR | 17.83% |
| 2022 Q4 | 70.9 Million EUR | 10.05% |
| 2022 Q3 | 64.42 Million EUR | 7.58% |
| 2021 Q1 | 56.05 Million EUR | 1.6% |
| 2021 FY | - EUR | 16.87% |
| 2021 Q4 | 58.8 Million EUR | 40.81% |
| 2021 Q3 | 41.75 Million EUR | -32.15% |
| 2021 Q2 | 61.54 Million EUR | 9.81% |
| 2020 Q4 | 55.16 Million EUR | 45.28% |
| 2020 FY | - EUR | 45.58% |
| 2020 Q3 | 37.97 Million EUR | -6.57% |
| 2020 Q2 | 40.64 Million EUR | 44.01% |
| 2020 Q1 | 28.22 Million EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alcon Inc. | 2.39 Billion USD | 88.619% |
| AptarGroup, Inc. | 663.83 Million USD | 58.974% |
| Baxter International Inc. | 2.77 Billion USD | 90.189% |
| Becton, Dickinson and Company | 2.42 Billion USD | 88.769% |
| Bausch + Lomb Corporation | 586 Million USD | 53.524% |
| Haemonetics Corporation | 262.09 Million USD | -3.911% |
| Envista Holdings Corp | 171.1 Million USD | -59.175% |
| ResMed Inc. | 1.6 Billion USD | 82.982% |
| Teleflex Incorporated | 792.26 Million USD | 65.624% |
| Warby Parker Inc. | -30.21 Million USD | 1001.456% |
| West Pharmaceutical Services, Inc. | 847.8 Million USD | 67.876% |